Vir Biotechnology (VIR) Cash & Equivalents (2018 - 2026)

Vir Biotechnology has reported Cash & Equivalents for 9 years, with the latest figure at $8.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 89.9% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 million (down 89.9% YoY) and the FY2025 annual result came in at $232.2 million, up 159.76% from the prior year.
• Cash & Equivalents declined to $8.9 million in Q1 2026 per VIR's latest filing, from $232.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.5 billion in Q2 2022 and troughed at $2.2 million in Q3 2025.
• A 5-year average of $313.9 million and a median of $168.4 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents surged 21390.33% in 2022, then sank 98.68% in 2025.
• Over 5 years, Cash & Equivalents stood at $12.7 million in 2022, then soared by 1805.02% to $241.6 million in 2023, then sank by 63.0% to $89.4 million in 2024, then surged by 159.76% to $232.2 million in 2025, then tumbled by 96.17% to $8.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $8.9 million, $232.2 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.